GlassScriptPhysician profile
Andrew Ravin
NPI 1669001764
$1,047.04
in general payments reported to CMS, 2019-2025
20 companies · $508 in 2025
The $508 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $131 · 2024: $408 · 2025: $508.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,047.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,047.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $169.46 | 2024-2025 | Korlym |
| Radius Health, INC. | $124.41 | 2023-2025 | Tymlos |
| Sanofi-Aventis U.S. LLC | $90.89 | 2023-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $85.36 | 2024-2025 | |
| Recordati_rare_diseases_inc. | $83.75 | 2023-2025 | Isturisa, Signifor Lar |
| Novo Nordisk INC | $72.15 | 2023-2025 | Rybelsus, Ozempic |
| Amgen INC. | $49.69 | 2024-2025 | Tepezza |
| Abbvie INC. | $49.04 | 2024 | |
| Madrigal Pharmaceuticals | $45.78 | 2025 | Rezdiffra |
| Xeris Pharmaceuticals, INC. | $45.50 | 2025 | Recorlev |
| Lilly USA, LLC | $39.85 | 2025 | Zepbound, Mounjaro |
| Medtronic, INC. | $35.01 | 2024 | Minimed 780g |
| Mannkind Corporation | $33.18 | 2023-2025 | Afrezza |
| Embecta Corp. | $27.21 | 2023-2024 | Bd Nano 2nd Gen Pen Needle |
| Pfizer INC. | $19.69 | 2024 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $17.00 | 2025 | Strensiq |
| Ascendis Pharma Endocrinology INC | $16.55 | 2023 | |
| Almatica Pharma LLC | $15.81 | 2024 | Teriparatide |
| Amphastar Pharmaceuticals, INC. | $13.78 | 2023 | Baqsimi |
| Ucb, INC. | $12.93 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Ravin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.